CLINICAL TRIALS PROFILE FOR INREBIC
✉ Email this page to a colleague
All Clinical Trials for INREBIC
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04955938 ↗ | A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | Not yet recruiting | University of Chicago | Phase 1 | 2021-10-01 | The purpose of this research is to gather information on the safety and effectiveness of fedratinib (a drug called a "jak inhibitor" ) in combination with ivosidenib or enasidenib (two anti-cancer drugs). While all three drugs are FDA-approved for various conditions, the US Food and Drug Administration (FDA) has not approved the combination of these drugs for the treatment of rare blood cancers that present Isocitrate dehydrogenase (IDH) mutations, and therefore these drugs can only be given in a research study. |
| NCT05127174 ↗ | Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms | Recruiting | Bristol-Myers Squibb | Phase 1/Phase 2 | 2021-11-09 | The purpose of the study is to evaluate the effectiveness and safety of fedratinib as maintenance therapy in participants with myeloproliferative neoplasms (MPNs) after allogeneic hematopoietic cell transplant (HCT). |
| NCT05127174 ↗ | Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | Phase 1/Phase 2 | 2021-11-09 | The purpose of the study is to evaluate the effectiveness and safety of fedratinib as maintenance therapy in participants with myeloproliferative neoplasms (MPNs) after allogeneic hematopoietic cell transplant (HCT). |
| NCT05177211 ↗ | Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) | Recruiting | Bristol-Myers Squibb | Phase 2 | 2021-12-15 | The purpose of the study is to evaluate the effectiveness, safety, and tolerability of a study drug called fedratinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) and chronic neutrophilic leukemia (CNL). |
| NCT05177211 ↗ | Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | 2021-12-15 | The purpose of the study is to evaluate the effectiveness, safety, and tolerability of a study drug called fedratinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) and chronic neutrophilic leukemia (CNL). |
| NCT05524857 ↗ | Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP) | Recruiting | Bristol-Myers Squibb | Phase 1 | 2022-09-01 | The purpose of this research is to study the safety and tolerability and to establish the maximum tolerated dose (MTD) of the combination of two drugs, fedratinib and decitabine, for the treatment of advanced-phase MPNs. |
| NCT05524857 ↗ | Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP) | Recruiting | Joseph Jurcic | Phase 1 | 2022-09-01 | The purpose of this research is to study the safety and tolerability and to establish the maximum tolerated dose (MTD) of the combination of two drugs, fedratinib and decitabine, for the treatment of advanced-phase MPNs. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for INREBIC
Condition Name
Clinical Trial Locations for INREBIC
Trials by Country
Clinical Trial Progress for INREBIC
Clinical Trial Phase
Clinical Trial Sponsors for INREBIC
Sponsor Name
